PTHS (Pelthos Therapeutics) LT-Debt-to-Total-Asset: 0.18 (As of Mar. 2026)


PTHS Pelthos Therapeutics Inc PTHS
8 GF Score
Price $29.03
! 5 Warning Signs
View Full Analysis

What is Pelthos Therapeutics LT-Debt-to-Total-Asset?

Pelthos Therapeutics PTHS -0.62% 8 LT-Debt-to-Total-Asset is 0.18 as of Mar. 2026. GuruFocus rates PTHS with a GF Score™ of 8/100. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pelthos Therapeutics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.18.

Pelthos Therapeutics's long-term debt to total assets ratio increased from Mar. 2025 (0.00) to Mar. 2026 (0.18). It may suggest that Pelthos Therapeutics is progressively becoming more dependent on debt to grow their business.

Pelthos Therapeutics  (AMEX:PTHS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pelthos Therapeutics LT-Debt-to-Total-Asset Related Terms

Pelthos Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Pelthos Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pelthos Therapeutics LT-Debt-to-Total-Asset Chart

Pelthos Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.26

Pelthos Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.02 0.26 0.18
PTHS
8GF Score
Pelthos Therapeutics Inc PTHS
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pelthos Therapeutics LT-Debt-to-Total-Asset Calculation

Pelthos Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=34.193/130.397
=0.26

Pelthos Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=25.935/145.378
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.18 mean?
Pelthos Therapeutics (PTHS) has a LT-Debt-to-Total-Asset of 0.18 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pelthos Therapeutics and its competitors.
Is Pelthos Therapeutics' LT-Debt-to-Total-Asset too high?
Pelthos Therapeutics' current LT-Debt-to-Total-Asset is 0.18. Overall, Pelthos Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Pelthos Therapeutics' LT-Debt-to-Total-Asset compare to CGTX and BDTX?
Pelthos Therapeutics' LT-Debt-to-Total-Asset of 0.18 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Pelthos Therapeutics and its competitors. Pelthos Therapeutics's current LT-Debt-to-Total-Asset is 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pelthos Therapeutics stock overvalued right now?
Pelthos Therapeutics (PTHS) has a current LT-Debt-to-Total-Asset of 0.18. The current LT-Debt-to-Total-Asset is 0.18. Pelthos Therapeutics' overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Pelthos Therapeutics (PTHS), the current LT-Debt-to-Total-Asset is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pelthos Therapeutics Business Description

Address 4020 Stirrup Creek Drive, Suite 110, Durham, NC, USA, 27703
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
8GF Score

Get the complete analysis for PTHS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.03
Price